• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Immunization with Cross-conserved H1N1 Influenza CD4+ T Cell Epitopes Lowers Viral Burden in HLA DR3 Transgenic Mice

Immunization with Cross-conserved H1N1 Influenza CD4+ T Cell Epitopes Lowers Viral Burden in HLA DR3 Transgenic Mice

by Adam | Oct 22, 2016

Hum Vaccin Immunother. 2013 Sep 17;9(10).
iVAX: A Sophisticated Suite of Online Vaccine Design Tools

iVAX: A Sophisticated Suite of Online Vaccine Design Tools

by Adam | Oct 22, 2016

Immunogenicity of Teffector and Treg epitopes from H7N9 avian-origin influenza: Impact of cross-reactivity with the human genome

Immunogenicity of Teffector and Treg epitopes from H7N9 avian-origin influenza: Impact of cross-reactivity with the human genome

by Adam | Oct 22, 2016

Cross-reactive influenza H1N1 T cell epitopes identified by immunoinformatic methods stimulate CD4+ T cell responses

Cross-reactive influenza H1N1 T cell epitopes identified by immunoinformatic methods stimulate CD4+ T cell responses

by Adam | Oct 22, 2016

FastVax: Making vaccines “on demand” A potential solution for emerging pathogens and biodefense?

FastVax: Making vaccines “on demand” A potential solution for emerging pathogens and biodefense?

by Adam | Oct 22, 2016

« Older Entries
Next Entries »

Recent Posts

  • EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services    
  • Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy

Recent Comments

No comments to show.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

This website uses cookies and similar technologies to collect information about your website experience for advertising, analytics, and other purposes as described in our Privacy Policy.